5 ETFs to Make the Most of Eli Lilly's Strength
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Eli Lilly's Strong Q2 Performance: Eli Lilly reported impressive second-quarter results for 2024, with earnings per share of $3.92 and revenues of $11.3 billion, driven by significant sales growth in diabetes and weight-loss drugs, leading to a 9.5% increase in shares post-announcement.
Increased Outlook and ETF Opportunities: Following the strong earnings, Eli Lilly raised its full-year revenue guidance and several analysts upgraded their stock targets; investors are encouraged to consider ETFs with high exposure to Eli Lilly, such as iShares U.S. Pharmaceuticals ETF and Roundhill GLP-1 & Weight Loss ETF.
Analyst Views on MEDX
Wall Street analysts forecast MEDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 34.130
Low
Averages
High
Current: 34.130
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
